Orexigen Therapeutics (OREX) Remains Outperform Rated at Wells Fargo

Wells Fargo maintained an Outperform rating on Orexigen Therapeutics (NASDAQ: OREX) with a price target of $9.50-$10.50. Earlier it reported Q3 results.

In the view of analyst Matthew J. Andrews, there were a number of signals that suggest early launch of Contrave has gotten off to a good start. Andrews made note of management comments that suggest scrips appear to be under counted. He also noted management remains optimistic on prospects for a positive CHMP recommendation. Overall Andrews views Orexigen as under-valued, and it remains on of the firm's favorite small cap ideas

For an analyst ratings summary and ratings history on Orexigen Therapeutics click here. For more ratings news on Orexigen Therapeutics click here.

Shares of Orexigen Therapeutics closed at $3.85 yesterday.

You May Also Be Interested In

• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• AMD (AMD) to offer senior notes in four parts
• UBS Reiterates Buy Rating on HF Sinclair (DINO)